Comparative Pharmacology
Head-to-head clinical analysis: AFINITOR versus AFINITOR DISPERZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFINITOR versus AFINITOR DISPERZ.
AFINITOR vs AFINITOR DISPERZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibitor of mammalian target of rapamycin (mTOR), specifically the mTORC1 complex, by binding to the FKBP-12 protein, reducing cell proliferation, angiogenesis, and glucose uptake.
Everolimus is an mTOR inhibitor that binds to FKBP-12, forming a complex that inhibits the mTOR serine-threonine kinase, thereby blocking cell cycle progression, angiogenesis, and cell growth.
10 mg orally once daily for advanced breast cancer, neuroendocrine tumors, and renal cell carcinoma; 10 mg orally once daily for subependymal giant cell astrocytoma (SEGA) in adults; 5 mg/m^2 orally once daily for SEGA in pediatric patients (titrated to trough levels 5-15 ng/mL).
10 mg orally once daily for advanced hormone receptor-positive, HER2-negative breast cancer; 10 mg orally once daily for advanced pancreatic neuroendocrine tumors; 10 mg orally once daily for advanced renal cell carcinoma; 7.5 mg orally once daily for subependymal giant cell astrocytoma (SEGA); 5 mg orally once daily for tuberous sclerosis complex (TSC)-associated renal angiomyolipoma.
None Documented
None Documented
Terminal elimination half-life: 30 hours (range 15–40 hours) in healthy subjects; increases to 40–70 hours in moderate hepatic impairment.
Terminal half-life is approximately 30 hours (range 28-35 hours) in patients with advanced solid tumors, supporting once-daily dosing.
Primarily fecal (80%) and renal (5%) as unchanged drug and metabolites. Biliary excretion is significant.
Primarily fecal (80%) with 22% as unchanged drug; renal excretion <5%.
Category C
Category C
mTOR Inhibitor Antineoplastic
mTOR Inhibitor Antineoplastic